0.00
100.00%
-1.54
Ngm Biopharmaceuticals Inc stock is currently priced at $0.00, with a 24-hour trading volume of 0.
It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.55 pivot point. If it approaches the $1.50 support level, significant changes may occur.
Previous Close:
$1.54
Open:
$0
24h Volume:
0
Market Cap:
$128.53M
Revenue:
$4.42M
Net Income/Loss:
$-142.38M
P/E Ratio:
0.00
EPS:
-2.08
Net Cash Flow:
$-133.45M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
Ngm Biopharmaceuticals Inc Stock (NGM) Company Profile
Name
Ngm Biopharmaceuticals Inc
Sector
Industry
Phone
650-243-5555
Address
333 Oyster Point Boulevard, South San Francisco, CA
Ngm Biopharmaceuticals Inc Stock (NGM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-03-23 | Initiated | Citigroup | Buy |
Oct-18-22 | Downgrade | Goldman | Buy → Neutral |
Oct-18-22 | Downgrade | Raymond James | Strong Buy → Outperform |
Oct-17-22 | Downgrade | Jefferies | Buy → Hold |
Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-20-22 | Initiated | Jefferies | Buy |
Sep-13-21 | Upgrade | Raymond James | Outperform → Strong Buy |
May-24-21 | Downgrade | Raymond James | Strong Buy → Outperform |
Jul-31-20 | Initiated | Piper Sandler | Overweight |
Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
Apr-07-20 | Initiated | Raymond James | Strong Buy |
Oct-17-19 | Initiated | B. Riley FBR | Buy |
Jun-25-19 | Initiated | Stifel | Buy |
Apr-29-19 | Initiated | Citigroup | Buy |
Apr-29-19 | Initiated | Cowen | Outperform |
Apr-29-19 | Initiated | Goldman | Buy |
View All
Ngm Biopharmaceuticals Inc Stock (NGM) Latest News
NGM Bio Announces Closing of Tender Offer
GlobeNewswire Inc.
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
GlobeNewswire Inc.
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
Zacks Investment Research
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Ngm Biopharmaceuticals Inc Stock (NGM) Financials Data
Ngm Biopharmaceuticals Inc (NGM) Revenue 2024
NGM reported a revenue (TTM) of $4.42 million for the quarter ending December 31, 2023, a -92.02% decline year-over-year.
Ngm Biopharmaceuticals Inc (NGM) Net Income 2024
NGM net income (TTM) was -$142.38 million for the quarter ending December 31, 2023, a +12.47% increase year-over-year.
Ngm Biopharmaceuticals Inc (NGM) Cash Flow 2024
NGM recorded a free cash flow (TTM) of -$133.45 million for the quarter ending December 31, 2023, a +8.78% increase year-over-year.
Ngm Biopharmaceuticals Inc (NGM) Earnings per Share 2024
NGM earnings per share (TTM) was -$1.73 for the quarter ending December 31, 2023, a +15.61% growth year-over-year.
About Ngm Biopharmaceuticals Inc
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity. Its products under development also comprise NGM120, an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in preclinical studies to decrease levels of a protein implicated in the dry form of age-related macular degeneration. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp., MedImmune Limited, and JDRF International. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):